Lifescience Opportunities in the Emerging Markets
By 2020 the pharmaceutical market is forecast to double to $1.3 trillion, with much of the growth coming from the emerging economies including primarily China and India. These two countries together with other emerging markets are expected to generate up to 20% of global sales by 2020.
Pharmaceutical and medical device companies worldwide are prioritizing Asia for its unsurpassed market potential. However, securing market access in China and India remains challenging and requires innovative programs for R&D investment, enhancement of local commercial capabilities, and addressing regulatory and IP hurdles. Our panel of experts will cover such topics as business development challenges, rewards and risks, new business models and possible impact of government policy and regulatory movements.
Please join us to hear first-hand experience from our panel which includes an entrepreneur, an investor and a representative from a multi national accounting and consulting company.
Panelists:
Min Cui, Ph.D., Venture Capital Investment Professional, Bay City Capital
Dr. Cui joined Bay City Capital in October 2006 and currently focuses on evaluation of investment opportunities for the firm. Dr. Cui founded or co-founded two biotech companies in the U.S. as well as a pharmaceutical company in China. Most recently he was Director of Strategic Investment Planning for Southern Research Institute, an organization that has discovered and developed six anti-cancer drugs approved by the FDA. Dr. Cui served as Chief Scientific Officer of Pan Pacific Pharmaceuticals from 1998 to 2002 and of Huanuo Biopharmaceuticals from 2003 to 2005. In these positions, he led efforts in evaluating and acquiring several key technologies in the fields of cancer, infectious and inflammatory diseases. He received his Ph.D. degree in Cancer Biology from Stanford University, and a B.S. degree in Molecular Biology from Peking University.
Anula Jayasuriya, MD, PhD, MBA is a life science venture capitalist.
Dinesh Patel is the President and CEO of Arête Therapeutics (www.aretetherapeutics.com), and brings more than 22 years of experience in the pharmaceutical and biotech industry. Arête is a privately held and adequately financed ($51 million in Series A funding) pharmaceutical Company discovering and developing ‘first in class’ small molecule antihypertensive drugs directed at a novel target for cardiovascular and anti-inflammatory diseases. Dr. Patel was formerly the President, COO & Co-founder of Miikana Therapeutics, a privately-held company focused on targeted oncology drug discovery and development until it was acquired by Entremed Inc in December 2005. He was part of the founding management and scientific team that incubated the anti-infective Company Vicuron (previously named Versicor) and held positions of increasing responsibility from 1996 to 2003 including Senior VP of Licensing & Drug Discovery. Vicuron was acquired by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, he was a Director at Affymax, which was acquired by GSK in 1995. He started his career as a medicinal chemist at Bristol-Myers Squibb in 1985. Dr. Patel has more than 100 patents and publications to his credit. He received his Ph.D. in organic chemistry from Rutgers, The State University of New Jersey and conducted post-doctoral research at the University of Wisconsin, Madison.
